Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.

[1]  Oliver Hartmann,et al.  Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. , 2010, American journal of respiratory and critical care medicine.

[2]  J. Struck,et al.  Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. , 2010, Journal of the American College of Cardiology.

[3]  N. Morgenthaler,et al.  Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections , 2010, Critical care.

[4]  T. Mueller,et al.  Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. , 2010, Clinical biochemistry.

[5]  P. Ponikowski,et al.  Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2010, Journal of the American College of Cardiology.

[6]  P. Ponikowski,et al.  Mid‐regional pro‐adrenomedullin as a novel predictor of mortality in patients with chronic heart failure , 2010, European journal of heart failure.

[7]  L. Tavazzi,et al.  The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial , 2010, European journal of heart failure.

[8]  N. Morgenthaler,et al.  Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. , 2009, Clinical biochemistry.

[9]  G. Fonarow,et al.  Cardiac troponin and outcome in acute heart failure. , 2008, The New England journal of medicine.

[10]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[11]  J. Struck,et al.  Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. , 2007, Journal of the American College of Cardiology.

[12]  J. Struck,et al.  Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. , 2007, Journal of cardiac failure.

[13]  J. Struck,et al.  Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. , 2005, Clinical chemistry.

[14]  J. Struck,et al.  Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients , 2004, Peptides.

[15]  J. Burnett,et al.  Adrenomedullin: potential in physiology and pathophysiology. , 2000, Life sciences.

[16]  R. Rodeheffer,et al.  Cardiac secretion of adrenomedullin in human heart failure. , 1996, The Journal of clinical investigation.

[17]  T. Ishimitsu,et al.  Increased plasma levels of adrenomedullin in patients with heart failure. , 1995, Journal of the American College of Cardiology.

[18]  J. Burnett,et al.  Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. , 1995, Circulation.